Lifeward Seeks Reverse Stock Split, Capital Increase Approval

TL;DR

**LFWD is gearing up for a reverse split and capital hike – a clear signal they're trying to boost their stock price and set up for future fundraising, so watch for volatility.**

AI Summary

Lifeward Ltd. (LFWD) is convening an Extraordinary General Meeting of Shareholders on January 6, 2026, to address critical corporate structure changes. The primary proposal, Proposal 1, seeks shareholder authorization for the Board of Directors to implement a reverse share split of the company's ordinary shares, with a potential ratio ranging from 1-for-2 to 1-for-12. This action is typically pursued to increase share price and meet listing requirements. Proposal 2, contingent on the approval of Proposal 1 and the Board's decision to proceed with a reverse split, requests approval to increase the company's authorized share capital. Finally, Proposal 3 aims to amend the company's Seventh Amended and Restated Articles of Association to eliminate the par value of its ordinary shares, a move that can simplify capital structure and provide greater financial flexibility. The Board of Directors unanimously recommends voting "FOR" all three proposals, which each require an Ordinary Majority for approval. As of the November 26, 2025 record date, there were 18,293,776 ordinary shares outstanding and entitled to vote.

Why It Matters

These proposals are crucial for Lifeward Ltd. as a reverse share split could significantly impact its stock price, potentially helping it meet exchange listing requirements and attract institutional investors, thereby improving liquidity. An increase in authorized share capital, if approved, would give the company flexibility for future equity financing, mergers, or employee incentive plans, which could dilute existing shareholders if not managed carefully. Eliminating par value simplifies accounting and corporate governance, aligning Lifeward with modern corporate practices and potentially reducing administrative burdens. Competitively, these structural changes could position Lifeward more favorably against peers by enhancing its financial profile and strategic agility in the market.

Risk Assessment

Risk Level: medium — The primary risk stems from the proposed reverse share split (Proposal 1), which, while intended to increase share price, often fails to sustain long-term value and can be perceived negatively by the market. Historically, reverse splits can lead to further price declines if underlying business fundamentals do not improve. The potential increase in authorized share capital (Proposal 2) also carries dilution risk for existing shareholders if new shares are issued without corresponding value creation.

Analyst Insight

Investors should closely monitor the outcome of the January 6, 2026 Extraordinary General Meeting and the subsequent market reaction to any reverse share split. Consider the company's underlying financial performance and strategic initiatives beyond these structural changes before making any investment decisions, as a reverse split alone does not guarantee improved shareholder value.

Key Numbers

• 1-for-2 to 1-for-12 — Reverse share split ratio range (Board authorized to set ratio for Proposal 1)
• 18,293,776 — Ordinary shares outstanding (As of the November 26, 2025 record date, entitled to vote)
• NIS 1.75 — Par value per ordinary share (Current par value, subject to elimination under Proposal 3)
• January 6, 2026 — Extraordinary General Meeting date (Shareholders will vote on proposals)
• 10:00 a.m. EST — Meeting start time (Time of the Extraordinary General Meeting)
• 200 Donald Lynch Blvd., Marlborough, MA 01752 — Meeting location (Company's offices where the meeting will be held)

Key Players & Entities

• Lifeward Ltd. (company) — Registrant and subject of the DEF 14A filing
• Joseph Turk (person) — Chairman of the Board of Directors and proxy representative
• Mark Grant (person) — Proxy representative
• SEC (regulator) — Securities and Exchange Commission
• Equiniti Trust Company, LLC (company) — Transfer agent for Lifeward Ltd.
• 18,293,776 (dollar_amount) — Ordinary shares outstanding as of November 26, 2025
• NIS 1.75 (dollar_amount) — Par value of ordinary shares
• January 6, 2026 (date) — Date of the Extraordinary General Meeting
• December 1, 2025 (date) — Mailing date of proxy materials
• November 26, 2025 (date) — Record date for voting eligibility

FAQ

Risk Factors

• Reverse Stock Split Impact on Share Price [medium — market]: The primary goal of the proposed reverse share split (Proposal 1) is to increase the per-share trading price of Lifeward Ltd.'s ordinary shares. The range of 1-for-2 to 1-for-12 indicates a significant potential adjustment. Failure to achieve a sustained increase in share price post-split could lead to continued delisting concerns or negative market perception.
• Meeting Listing Requirements [high — regulatory]: The reverse share split is likely intended to meet minimum bid price requirements for continued listing on a stock exchange. If the company's share price falls below these thresholds, the reverse split is a common corrective action. Failure to maintain listing could result in significant liquidity issues for shareholders.
• Share Capital Increase Contingency [medium — financial]: Proposal 2, contingent on the reverse split, seeks to increase authorized share capital. This could be to provide flexibility for future financing or stock-based compensation, but it also dilutes existing shareholders if new shares are issued without a corresponding increase in company value.
• Elimination of Par Value [low — financial]: Proposal 3 aims to eliminate the NIS 1.75 par value per ordinary share. This simplifies the capital structure and can provide greater financial flexibility, but it removes a nominal legal barrier that previously existed for share issuance.

Industry Context

Lifeward Ltd. operates in the biotechnology or medical device sector, where maintaining compliance with stock exchange listing requirements is crucial for investor confidence and access to capital. Companies in this space often face pressure to demonstrate growth and stability, making corporate actions like reverse splits a tool to manage share price and market perception.

Regulatory Implications

The proposed reverse share split is a direct response to potential or actual non-compliance with stock exchange minimum bid price rules. Failure to rectify this could lead to delisting, impacting liquidity and investor confidence. The elimination of par value simplifies capital structure but removes a nominal legal constraint.

What Investors Should Do

1. Review the rationale for the reverse share split (Proposal 1) and its potential impact on share price and liquidity.
2. Evaluate the implications of increasing authorized share capital (Proposal 2) in conjunction with the reverse split.
3. Consider the benefits and drawbacks of eliminating the NIS 1.75 par value per share (Proposal 3).
4. Vote on all three proposals, as the Board of Directors unanimously recommends voting 'FOR' each.

Key Dates

• 2025-11-26: Record Date for Extraordinary General Meeting — Establishes the list of shareholders entitled to vote at the meeting.
• 2025-12-01: Proxy Statement Availability — Shareholders receive the official documentation outlining the proposals and recommendations.
• 2026-01-06: Extraordinary General Meeting — Shareholders will vote on critical corporate structure changes, including a reverse share split and amendments to share capital.

Glossary

Reverse Share Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. This is often done to increase the per-share market price. (Proposal 1 seeks shareholder authorization for the Board to implement a reverse share split with a ratio between 1-for-2 and 1-for-12.)

Authorized Share Capital

The maximum number of shares a company is legally permitted to issue, as specified in its articles of incorporation or association. (Proposal 2, contingent on a reverse split, requests approval to increase Lifeward Ltd.'s authorized share capital.)

Par Value

A nominal value assigned to a share of stock by the company's charter. It has little relation to the market value and is primarily an accounting and legal concept. (Proposal 3 aims to eliminate the current par value of NIS 1.75 for Lifeward Ltd.'s ordinary shares.)

Articles of Association

A document that, along with the memorandum of association, governs the relationship between a company and its shareholders and directors. It outlines the company's internal rules and procedures. (Amendments to Lifeward Ltd.'s Seventh Amended and Restated Articles of Association are required for Proposals 1, 2, and 3.)

Ordinary Majority

A voting threshold requiring more than 50% of the votes cast by shareholders present and voting at a meeting. (All three proposals require an Ordinary Majority for approval.)

Year-Over-Year Comparison

This filing is a proxy statement for an Extraordinary General Meeting, not a comprehensive annual report like a 10-K. Therefore, direct year-over-year comparisons of financial metrics such as revenue, net income, or margins are not available in this document. The focus is on proposed corporate actions rather than historical financial performance.

Filing Documents

• zk2534075.htm (DEF 14A) — 269KB
• image0.jpg (GRAPHIC) — 340KB
• 0001178913-25-003970.txt ( ) — 738KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 7 PROPOSAL 1 – AUTHORIZATION OF THE BOARD OF DIRECTORS TO DETERMINE WHETHER TO EFFECT A REVERSE SHARE SPLIT OF THE COMPANY'S OUTSTANDING ORDINARY SHARES, PAR VALUE NIS 1.75 EACH, AND IF SO, TO SET A RATIO WITHIN A RANGE OF 1-FOR-2 TO 1-FOR-12, TO BE EFFECTIVE ON A DATE TO BE DETERMINED BY THE BOARD, AND TO APPROVE CONFORMING AMENDMENTS TO THE COMPANY'S SEVENTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION TO REFLECT ANY SUCH REVERSE SHARE SPLIT 8 PROPOSAL 2 – SUBJECT TO THE APPROVAL OF PROPOSAL 1, AND IF THE BOARD DETERMINES TO EFFECT A REVERSE SHARE SPLIT PURSUANT THERETO, TO APPROVE AMENDMENTS TO THE COMPANY'S SEVENTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION AUTHORIZING AN INCREASE IN THE COMPANY'S AUTHORIZED SHARE CAPITAL 15 PROPOSAL 3 – APPROVAL OF AN AMENDMENT TO THE COMPANY'S SEVENTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION TO ELIMINATE THE PAR VALUE OF THE COMPANY'S ORDINARY SHARES 18 OTHER BUSINESS 19 ADDITIONAL INFORMATION 19 Lifeward Ltd. 200 Donald Lynch Blvd., Marlborough, MA 01752, U.S.A. Tel: +1 508.251.1154 PROXY STATEMENT This Proxy Statement is being furnished to the holders of ordinary shares, par value NIS 1.75 each, of Lifeward Ltd. ("we," the "Company", or "Lifeward") in connection with the solicitation of proxies by our Board of Directors (the "Board" or the "Board of Directors") for use at an Extraordinary General Meeting of Shareholders (the "Meeting") to be held at the Company's offices at 200 Donald Lynch Blvd., Marlborough, MA 01752, U.S.A. at 10:00 a.m. (Eastern Standard Time) on Tuesday, January 6, 2026, at and at any adjournment or postponement thereof, pursuant to the accompanying Notice of Extraordinary General Meeting of Shareholders. We are first making available this Proxy Statement and accompanying materials to shareholders on or about December 1, 2025. The agenda of the Meeting will be as follows: 1. To authorize the Board of Directo

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT As of November 27, 2025, there were 18,293,776 ordinary shares outstanding, excluding ordinary shares issuable in connection with the exercise of outstanding warrants or outstanding options, upon the vesting and settlement of restricted stock un

View Full Filing

View this DEF 14A filing on SEC EDGAR